1007883-14-8Relevant academic research and scientific papers
Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir
Belema, Makonen,Nguyen, Van N.,Bachand, Carol,Deon, Dan H.,Goodrich, Jason T.,James, Clint A.,Lavoie, Rico,Lopez, Omar D.,Martel, Alain,Romine, Jeffrey L.,Ruediger, Edward H.,Snyder, Lawrence B.,Laurent, Denis R. St.,Yang, Fukang,Zhu, Juliang,Wong, Henry S.,Langley, David R.,Adams, Stephen P.,Cantor, Glenn H.,Chimalakonda, Anjaneya,Fura, Aberra,Johnson, Benjamin M.,Knipe, Jay O.,Parker, Dawn D.,Santone, Kenneth S.,Fridell, Robert A.,Lemm, Julie A.,O'Boyle, Donald R.,Colonno, Richard J.,Gao, Min,Meanwell, Nicholas A.,Hamann, Lawrence G.
, p. 2013 - 2032 (2014)
The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1-6. However, these compounds exhibit
HEPATITIS C VIRUS INHIBITORS
-
, (2009/10/09)
The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 172, (2008/06/13)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
